Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197942 | 0.93 | MCHR1 (0.49) | MCHR1EPHX2PPARATRPV1MAPT | |
| SCHEMBL13197771 | 0.92 | MCHR1 (0.43) | MCHR1EPHX2PPARATRPV1MAPT | |
| SCHEMBL13206932 | 0.90 | MCHR1 (0.42) | MCHR1EPHX2PPARATRPV1MAPT | |
| SCHEMBL13197937 | 0.88 | EPHX2 (0.45) | MCHR1EPHX2PPARATRPV1MAPT | |
| SCHEMBL13197939 | 0.87 | MCHR1 (0.40) | MCHR1EPHX2PPARATRPV1MAPT | |
| SCHEMBL13197936 | 0.86 | EPHX2 (0.40) | MCHR1EPHX2PPARATRPV1MAPT | |
| SCHEMBL2565710 | 0.86 | MCHR1 (0.46) | MCHR1EPHX2PPARATRPV1MAPT | |
| SCHEMBL2561907 | 0.86 | MCHR1 (0.46) | MCHR1EPHX2PPARATRPV1MAPT | |
| SCHEMBL13197940 | 0.86 | EPHX2 (0.52) | EPHX2 | |
| SCHEMBL13197944 | 0.84 | MCHR1 (0.43) | MCHR1EPHX2PPARATRPV1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732901-B1 | ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND | AICURIS GMBH & CO KG (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | IRF3, EIF2AK2, ZC3HAV1 | MCHR1 4719/4885EPHX2 3922/4885PPARA 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.